BDBM504310 3α,7α,11β-trihydroxy-6α-ethyl-22-(1,2,4-oxadiazol-5-oxo-3-yl)-23,24-bisnor-5β-cholane ::US11034717, Compound 6
SMILES: CC[C@H]1[C@@H](O)C2C3CC[C@H]([C@H](C)Cc4nc(=O)o[nH]4)[C@@]3(C)C[C@H](O)C2[C@@]2(C)CC[C@@H](O)C[C@@H]12
InChI Key:
Data: 5 EC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 42 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 42 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
FMR1 autosomal homolog 1 (Dog) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB UniProtKB/TrEMBL GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 800 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Rat) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 240 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Mouse) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 270 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair |